AlphaTON Capital Corp. (ATON)
| Market Cap | 30.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.77M |
| Shares Out | 5.88M |
| EPS (ttm) | -5.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 199,589 |
| Open | 5.23 |
| Previous Close | 5.31 |
| Day's Range | 4.97 - 5.49 |
| 52-Week Range | 2.95 - 15.82 |
| Beta | 0.60 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 25, 2025 |
About ATON
AlphaTON Capital Corp., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage prog... [Read more]
Financial Performance
Financial StatementsNews
AlphaTON Capital Joins Blockchain Game Alliance (BGA)
Move Deepens Telegram/TON Gaming Strategy Following Intent to Acquire 51% of GAMEE Move Deepens Telegram/TON Gaming Strategy Following Intent to Acquire 51% of GAMEE
AACR Abstract: First Evidence that Selective A2B Receptor Inhibition Lowers PD-L1 Tumor Expression and also Directly Suppresses Mesothelioma Tumor Growth
Abstract published today reports reduced adenosine-mediated PD-L1 in a human epithelioid mesothelioma cell line linked to decreased CREB phosphorylation (pCREB). In vivo, TT-4 monotherapy outperformed...
Enzo Villani, Chief Investment Officer of AlphaTON Capital, to Speak at the Vatican's 10th Anniversary World Changers Summit
Vatican City, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Enzo Villani, Chief Investment Officer of AlphaTON Capital ( NASDAQ: ATON), has been invited to speak at the 10th Anniversary of the IASC World Changer...
AlphaTON Capital Powers TOKEN2049 “Origins” Hackathon in Singapore
Awards $25,000 Prize Pool to Global TON Builders Across AI, Payments, and Infrastructure Awards $25,000 Prize Pool to Global TON Builders Across AI, Payments, and Infrastructure
How AlphaTON (ATON) is Funding Cancer Research Through Tokenization
Anthony Scaramucci and Brittany Kaiser explain how AlphaTON are using digital assets to fund cancer research and launch companies within blockchain and the “Telegram ecosystem.” AlphaTON (ATON) owns m...
AlphaTON Capital CEO Brittany Kaiser and SkyBridge Capital Founder Anthony Scaramucci Join Schwab Network's Trading 360 to Discuss Crypto Innovation and Cancer Research Funding
Dover, DE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) today announced that its CEO, Brittany Kaiser, will appear alongside Anthony Scaramucci, Founder of SkyBridge Capital...
AlphaTON Capital Launches AI Vertical with MorpheusAI to Accelerate Agentic AI Development on TON and Telegram
Landmark Strategic Partnership Establishes Morpheus as Preferred AI Infrastructure Provider for AlphaTON's Portfolio Companies Landmark Strategic Partnership Establishes Morpheus as Preferred AI Infra...
AlphaTON Capital CIO and Executive Chairman Enzo Villani Featured in Live Interview at Nasdaq MarketSite with IPO Edge
Dover, DE, Oct. 09, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON), a specialized digital asset treasury company focused on the TON blockchain and Telegram ecosystem, today announced t...
AlphaTON Capital and Subsidiary Cyncado Therapeutics Pioneer Convergence of Digital Assets and Oncology Innovation: Exploring Tokenization Framework for Mesothelioma Program as it Advances Toward Q1 2026 First Patient Dosing
Dover, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) ("AlphaTON" or the "Company"), alongside its wholly owned oncology subsidiary Tarus Therapeutics, LLC (dba Cyncado The...
Animoca Brands and AlphaTON Capital announce equity and token investments; AlphaTON intends to acquire GAMEE
Singapore, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Animoca Brands, the company driving digital property rights to help establish the open metaverse and its associated network effects, and AlphaTON Capital ...
Health In Tech and AlphaTON Capital Sign Strategic Letter of Intent to Develop HITChain
an innovative blockchain- powered healthcare insurance claims processing platform built on The Open Network (TON). STUART, Fla.
AlphaTON Capital Corp Successfully Closes $71 million Financing and Completes Initial TON Token Acquisition
DOVER, Del., Sept. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp ("AlphaTON Capital" or the "Company") (Nasdaq: ATON), a specialized digital asset treasury company focused on the Telegram ecosyst...
AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem
AlphaTON Capital Unlocks Public Market Access to Toncoin (TON) and Telegram's Billion-User Ecosystem Brittany Kaiser, pioneer in data protection, digital assets, and the public equity markets appointe...
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Is...
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Is...
Portage Biotech and Compedica Stock-for-Stock Exchange
DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce th...
Portage Biotech Stock Surges As It Prepares For Human Trial
Portage Biotech's PORT-7 showed >90% tumor growth inhibition with anti-PD1 combo in a murine mesothelioma model. PORT-7 single-agent activity outperformed anti-PD1 treatment alone; first-in-human tria...
Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a ...
Why Is Portage Biotech Stock Skyrocketing Friday?
Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.
Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial
Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.
Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial
Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients Encouraging Safety Profile Supports Progression Toward First Dual-Admi...
Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, ...
Portage Biotech Announces Completion of $2.15 Million Private Financing
DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, ...
Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company
WESTPORT, Conn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeuti...
Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter
No impact at this time on the listing of the Company's Ordinary Shares on Nasdaq Company intends to submit to Nasdaq a compliance plan WESTPORT, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotec...